Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
72.7 GBX | +1.89% | +8.02% | -17.95% |
26/04 | Peel Hunt cuts ConvaTec to 'reduce' | AN |
22/04 | Jefferies Cuts Dr. Martens PT, Keeps Sector Perform Rating | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Footwear
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.95% | 871M | C+ | ||
+24.69% | 21.39B | B+ | ||
+21.58% | 10.31B | C+ | ||
+4.92% | 10.21B | C | ||
-6.73% | 8.54B | - | ||
+34.25% | 7.61B | B- | ||
-13.48% | 6.99B | A- | ||
+16.67% | 3.26B | A- | ||
+65.97% | 2.95B | B- | ||
-8.00% | 2.48B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DOCS Stock
- Ratings Dr. Martens plc